Compare ASTRAZENECA PHARMA with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs TORRENT PHARMA - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA TORRENT PHARMA ASTRAZENECA PHARMA/
TORRENT PHARMA
 
P/E (TTM) x 115.3 44.0 261.9% View Chart
P/BV x 33.7 10.5 320.2% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 ASTRAZENECA PHARMA   TORRENT PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
TORRENT PHARMA
Mar-19
ASTRAZENECA PHARMA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs1,2781,964 65.1%   
Low Rs8831,245 70.9%   
Sales per share (Unadj.) Rs228.4453.4 50.4%  
Earnings per share (Unadj.) Rs10.425.8 40.2%  
Cash flow per share (Unadj.) Rs16.362.3 26.1%  
Dividends per share (Unadj.) Rs017.00 0.0%  
Dividend yield (eoy) %01.1 0.0%  
Book value per share (Unadj.) Rs98.8279.2 35.4%  
Shares outstanding (eoy) m25.00169.22 14.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.73.5 133.7%   
Avg P/E ratio x104.262.2 167.5%  
P/CF ratio (eoy) x66.425.8 257.9%  
Price / Book Value ratio x10.95.7 190.3%  
Dividend payout %065.9 0.0%   
Avg Mkt Cap Rs m27,008271,513 9.9%   
No. of employees `0001.413.6 10.0%   
Total wages/salary Rs m1,53514,038 10.9%   
Avg. sales/employee Rs Th4,210.95,642.6 74.6%   
Avg. wages/employee Rs Th1,132.21,032.4 109.7%   
Avg. net profit/employee Rs Th191.1320.9 59.6%   
INCOME DATA
Net Sales Rs m5,71076,728 7.4%  
Other income Rs m123571 21.5%   
Total revenues Rs m5,83377,299 7.5%   
Gross profit Rs m46319,831 2.3%  
Depreciation Rs m1476,177 2.4%   
Interest Rs m05,038 0.0%   
Profit before tax Rs m4389,187 4.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,570 0.0%   
Tax Rs m1791,254 14.3%   
Profit after tax Rs m2594,363 5.9%  
Gross profit margin %8.125.8 31.4%  
Effective tax rate %40.813.6 299.3%   
Net profit margin %4.55.7 79.8%  
BALANCE SHEET DATA
Current assets Rs m3,20950,375 6.4%   
Current liabilities Rs m2,07051,653 4.0%   
Net working cap to sales %20.0-1.7 -1,198.5%  
Current ratio x1.61.0 159.0%  
Inventory Days Days7292 78.6%  
Debtors Days Days3568 51.1%  
Net fixed assets Rs m79083,648 0.9%   
Share capital Rs m50846 5.9%   
"Free" reserves Rs m2,41946,397 5.2%   
Net worth Rs m2,46947,244 5.2%   
Long term debt Rs m039,129 0.0%   
Total assets Rs m4,605141,209 3.3%  
Interest coverage xNM2.8-  
Debt to equity ratio x00.8 0.0%  
Sales to assets ratio x1.20.5 228.2%   
Return on assets %5.66.7 84.5%  
Return on equity %10.59.2 113.6%  
Return on capital %17.712.3 143.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m30022,103 1.4%   
Fx outflow Rs m2,0155,522 36.5%   
Net fx Rs m-1,71516,581 -10.3%   
CASH FLOW
From Operations Rs m8817,981 0.5%  
From Investments Rs m-94-2,413 3.9%  
From Financial Activity Rs mNA-13,145 0.0%  
Net Cashflow Rs m-62,380 -0.2%  

Share Holding

Indian Promoters % 0.0 71.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 7.0 4.3%  
FIIs % 15.7 12.6 124.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 8.8 103.4%  
Shareholders   12,856 26,511 48.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   GSK PHARMA  NATCO PHARMA  DIVIS LABORATORIES  IPCA LABS  ALKEM LABORATORIES  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Flat; Power and Telecom Stocks Witness Buying(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 2.0% YoY). Sales on the other hand came in at Rs 20 bn (down 4.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

These 5 Smallcaps Deserve a Place in Your Coffee Can Portfolio(Profit Hunter)

Jul 28, 2020

When it comes to quality stocks, doing less is more.

Before You Buy Your First Electric Vehicle Consider Buying this Stock(Profit Hunter)

Jul 29, 2020

As competition intensifies in the electric vehicle space, only few will create huge wealth over the years.

Large Opportunities Are Coming Our Way

Aug 5, 2020

Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.

How to Buy Gold and Silver(Fast Profits Daily)

Jul 27, 2020

In this video I'll show you how to buy bullion the right way.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Aug 7, 2020 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - DR. DATSONS LABS COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS